Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomi

MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”

Eikon Therapeutics' (NASDAQ: EIKN - Get Free Report) lock-up period will end on Tuesday, August 4th.

US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consume

Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and tec

"Treating the first patient in TeLuRide-008 is a significant milestone for Eikon as we continue

MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon),

Presentations to cover updates across Eikon's clinical pipeline including:  Updated data from TeLuRi

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke

Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 66.9% to $6.31 during Thursda

Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical co

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the

Eikon Therapeutics is initiated with a cautious buy, leveraging industry-leading management and a ro

MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollm

Presentations to cover progress across Eikon's most advanced clinical-stage programs Updated data wi

ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-ex

Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform an

Eikon Therapeutics (NASDAQ:EIKN) reported quarterly losses of $(2.46) per share which beat the analy

MILLBRAE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”)

U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations

Wedbush analyst Robert Driscoll reiterates Eikon Therapeutics (NASDAQ:EIKN) with a Underperform a

Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Comp

EIKN (NASDAQ: EIKN - Get Free Report) has received an average rating of "Moderate Buy" from the seve

Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Eikon Therapeutics (NASDAQ:EIKN)

JP Morgan analyst Brian Cheng initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overw

Wall Street analysts changed outlook on top names. For all changes, upgrades, downgrades and initiat

B of A Securities analyst Jason Zemansky initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) w

Mizuho analyst Joseph Catanzaro initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Out

Morgan Stanley analyst Sean Laaman initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a

Wedbush analyst Robert Driscoll initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Und

Stock News Novo sues Hims over compounded weight-loss drugs: Novo Nordisk (NVO) filed suit to stop H

The U.S. is reportedly poised for a wave of significant IPOs, with Goldman Sachs projecting proceeds

Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are

Shares of drug developer Eikon Therapeutics opened 5.28% below their offer price in their Nasdaq deb

Drug developer Eikon ‍Therapeutics said on Wednesday it had raised $381.2 million in its U.S. initia

U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January

Drug developer Eikon ‍Therapeutics ​said on Wednesday it was targeting ‌a valuation of up to $908.2